Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma

Cancer Medicine

Volumn 5, Issue 9, 2016, Pages 2294-2301

  Iyer, Jayasri G ^a   Blom, Astrid ^a   Doumani, Ryan ^a   Lewis, Christopher ^a   Tarabadkar, Erica S ^a   Anderson, Austin ^a   Ma, Christine ^a   Bestick, Amy ^a   Parvathaneni, Upendra ^b   Bhatia, Shailender ^a   Nghiem, Paul ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; durability of response; Merkel cell carcinoma; metastatic; neuroendocrine tumor; progression free survival; response rate

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DURABILITY OF RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MEDICAL RECORD; MERKEL CELL TUMOR; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; TREATMENT RESPONSE; VOMITING;

EID: 84991105185     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.815     Document Type: Article

References (20)

1. Lemos, B. D., B. E. Storer, J. G. Iyer, et al. 2010. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J. Am. Acad. Dermatol. 63:751–761.
2. Feng, H., M. Shuda, Y. Chang, and P. S. Moore. 2008. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096–1100.
3. Paulson, K. G., J. G. Iyer, W. T. Simonson, et al. 2014. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am. J. Clin. Pathol. 142:452–458.
4. Paulson, K. G., J. G. Iyer, A. Blom, et al. 2013. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J. Invest. Dermatol. 133:642–646.
5. Allen, P. J., W. B. Bowne, D. P. Jaques, M. F. Brennan, K. Busam, and D. G. Coit. 2005. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J. Clin. Oncol. 23:2300–2309.
6. Santamaria-Barria, J. A., G. M. Boland, B. Y. Yeap, V. Nardi, D. Dias-Santagata, and J. C. Jr Cusack. 2013. Merkel cell carcinoma: 30-year experience from a single institution. Ann. Surg. Oncol. 20:1365–1373.
7. Miller, N. J., S. Bhatia, U. Parvathaneni, J. G. Iyer, and P. Nghiem. 2013. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr. Treat. Options Oncol. 14:249–263.
8. Travis, W. D. 2010. Advances in neuroendocrine lung tumors. Ann. Oncol. 21(Suppl 7): vii65–vii71.
9. Kalemkerian, G. P., W. Akerley, P. Bogner, et al. 2013. Small cell lung cancer. J. Natl. Compr. Canc. Netw. 11:78–98.
10. National Comprehensive Cancer Network. 2016. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. V.1.2016. Available at http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf (accessed 1 March 2016).
11. Tai, P. T., E. Yu, E. Winquist, et al. 2000. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J. Clin. Oncol. 18:2493–2499.
12. Voog, E., P. Biron, J. P. Martin, and J. Y. Blay. 1999. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85:2589–2595.
13. Ahronowitz, I. Z., A. I. Daud, S. P. Leong, et al. 2011. An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second ‘primary’ tumor. J. Cutan. Pathol. 38:801–807.
14. Eisenhauer, E. A., P. Therasse, J. Bogaerts, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45:228–247.
15. Kaplan, E. L., and P. Meier. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457–481.
16. Belani, C. P., J. S. Lee, M. A. Socinski, et al. 2005. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann. Oncol. 16:1069–1075.
17. Amable, L. 2016. Cisplatin resistance and opportunities for precision medicine. Pharmacol. Res. 106:27–36.
18. Skolekova, S., M. Matuskova, M. Bohac, et al. 2016. Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells. Cell Commun. Signal. 14:4.
19. Litterman, A. J., D. M. Zellmer, K. L. Grinnen, et al. 2013. Profound impairment of adaptive immune responses by alkylating chemotherapy. J. Immunol. 190:6259–6268.
20. Kang, D. H., M. T. Weaver, N. J. Park, B. Smith, T. McArdle, and J. Carpenter. 2009. Significant impairment in immune recovery after cancer treatment. Nurs. Res. 58:105–114.